CD47 and Miyoshi myopathy: TTI-622 (SIRPα-IgG4 Fc fusion protein, NCT03530683) and AO-176 (a humanized IgG2 anti-CD47 mAb, NCT04445701) are being evaluated as a monotherapy or a combination therapy with proteasome inhibitors and dexamethasone in R/R MM patients [113, 114].